IMP 1088
Alternative Names: IMP-1088Latest Information Update: 22 May 2023
At a glance
- Originator Imperial College of Science, Technology and Medicine
- Developer Exscientia; Myricx Pharma
- Class Antivirals; Dimethylamines; Indazoles; Pyrazoles; Small molecules
- Mechanism of Action Glycylpeptide N-tetradecanoyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
- Discontinued Common cold
Most Recent Events
- 11 May 2023 Early research in Cancer in United Kingdom (unspecified route) prior to May 2023 (Myricx Pharma website, May 2023)
- 28 Jun 2022 No recent reports of development identified for research development in Common cold in United Kingdom
- 05 Jun 2018 Chemical structure information added